Evidence map›Paper›PMID 26725939›Full record

ArticleScientific reports2016

Galangin sensitizes TRAIL-induced apoptosis through down-regulation of anti-apoptotic proteins in renal carcinoma Caki cells.

Min Ae Han, Dong Hee Lee, Seon Min Woo, Bo Ram Seo, Kyoung-Jin Min, Shin Kim, Jong-Wook Park, Sang Hyun Kim, Yung Hyun Choi, Taeg Kyu Kwon

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Galangin Triggers Eryptosis and Hemolysis Through CaInternational journal of molecular sciences · 2024
    Article
  5. Review
  6. TRAIL-Sensitizing Effects of Flavonoids in Cancer.International journal of molecular sciences · 2023
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Flavonoids in Kidney Health and Disease.Frontiers in physiology · 2018
    Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Min Ae HanDepartment of Immunology, School of Medicine, Keimyung University, 2800 Dalgubeoldaero, Dalseo-Gu, Daegu 704-701, South Korea.
Dong Hee LeeDepartment of Immunology, School of Medicine, Keimyung University, 2800 Dalgubeoldaero, Dalseo-Gu, Daegu 704-701, South Korea.
Seon Min WooDepartment of Immunology, School of Medicine, Keimyung University, 2800 Dalgubeoldaero, Dalseo-Gu, Daegu 704-701, South Korea.
Bo Ram SeoDepartment of Immunology, School of Medicine, Keimyung University, 2800 Dalgubeoldaero, Dalseo-Gu, Daegu 704-701, South Korea.
Kyoung-Jin MinDepartment of Immunology, School of Medicine, Keimyung University, 2800 Dalgubeoldaero, Dalseo-Gu, Daegu 704-701, South Korea.
Shin KimDepartment of Immunology, School of Medicine, Keimyung University, 2800 Dalgubeoldaero, Dalseo-Gu, Daegu 704-701, South Korea.
Jong-Wook ParkDepartment of Immunology, School of Medicine, Keimyung University, 2800 Dalgubeoldaero, Dalseo-Gu, Daegu 704-701, South Korea.
Sang Hyun KimDepartment of Pharmacology, School of Medicine, Kyungpook National University, Daegu, South Korea.
Yung Hyun ChoiDepartment of Biochemistry, College of Oriental Medicine, Dong-Eui University, Busan, South Korea.
Taeg Kyu KwonDepartment of Immunology, School of Medicine, Keimyung University, 2800 Dalgubeoldaero, Dalseo-Gu, Daegu 704-701, South Korea.
Keimyung University · KRDong-Eui University · KRKyungpook National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Galangin, bioflavonoids, has been shown anti-cancer properties in various cancer cells. In this study, we investigated whether galangin could enhance TRAIL-mediated apoptosis in TRAIL resistant renal carcinoma Caki cells. Galangin alone and TRAIL alone had no effect on apoptosis, while combined treatment with galangin and TRAIL significantly induced apoptosis in renal carcinoma (Caki, ACHN and A498) but not normal cells (normal mouse kidney cells and human normal mesangial cells). Galangin induced down-regulation of Bcl-2 protein at the transcriptional level via inhibition of NF-κB activation but not p53 pathway. Furthermore, galangin induced down-regulation of cFLIP, Mcl-1 and survivin expression at the post-translational levels, and the over-expression of Bcl-2, cFLIP, Mcl-1 and survivin markedly reduced galangin-induced TRAIL sensitization. In addition, galangin increased proteasome activity, but galangin had no effect on expression of proteasome subunits (PSMA5 and PSMD4). In conclusion, our investigation suggests that galangin is a potent candidate for sensitizer of TRAIL resistant cancer cell therapy.

Indexed as

Antineoplastic AgentsApoptosisCarcinoma, Renal CellCASP8 and FADD-Like Apoptosis Regulating ProteinCell Line, TumorDown-RegulationDrug Screening Assays, AntitumorDrug SynergismFlavonoidsGene Expression Regulation, NeoplasticHumansInhibitor of Apoptosis ProteinsKidney NeoplasmsMyeloid Cell Leukemia Sequence 1 ProteinNF-kappa BProteasome Endopeptidase ComplexAntineoplastic AgentsBCL2 protein, humanBIRC5 protein, humanCASP8 and FADD-Like Apoptosis Regulating ProteinCFLAR protein, humanFlavonoidsgalanginInhibitor of Apoptosis ProteinsMCL1 protein, humanMyeloid Cell Leukemia Sequence 1 ProteinNF-kappa BProteasome Endopeptidase ComplexProto-Oncogene Proteins c-bcl-2SurvivinTNF-Related Apoptosis-Inducing Ligand

Identifiers

PMID26725939
PMCPMC4698673
OpenAlexW2398974287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.